{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:12:53Z","timestamp":1780567973216,"version":"3.54.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin. J. Integr. Med."],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11655-023-3638-8","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T02:01:37Z","timestamp":1684375297000},"page":"655-664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine"],"prefix":"10.1007","volume":"29","author":[{"given":"Xue-yu","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"3638_CR1","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics\u20142021 update a report from the American Heart Association. Circulation 2021;143:e254\u2013e743.","journal-title":"Circulation"},{"key":"3638_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMra1606915","volume":"376","author":"JL Anderson","year":"2017","unstructured":"Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med 2017;376:2053\u20132064.","journal-title":"N Engl J Med"},{"key":"3638_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289\u20131367.","journal-title":"Eur Heart J"},{"key":"3638_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119\u2013177.","journal-title":"Eur Heart J"},{"key":"3638_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0140-6736(17)31927-X","volume":"390","author":"RA Byrne","year":"2017","unstructured":"Byrne RA, Stone GW, Ormiston J, et al. Coronary balloon angioplasty, stents, and scaffolds. Lancet 2017;390:781\u2013792.","journal-title":"Lancet"},{"key":"3638_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2021.08.003","volume":"340","author":"E Shlofmitz","year":"2021","unstructured":"Shlofmitz E, Torguson R, Zhang C, et al. Impact of intravascular ultrasound on outcomes following percutaneous coronary intervention for in-stent restenosis (iOPEN-ISR study). Int J Cardiol 2021;340:17\u201321.","journal-title":"Int J Cardiol"},{"key":"3638_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jcin.2016.11.059","volume":"10","author":"SH Rezkalla","year":"2017","unstructured":"Rezkalla SH, Stankowski RV, Hanna J, et al. Management of no-reflow phenomenon in the catheterization laboratory. JACC Cardiovasc Interv 2017;10:215\u2013223.","journal-title":"JACC Cardiovasc Interv"},{"key":"3638_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.hjc.2019.04.007","volume":"61","author":"I Andreou","year":"2020","unstructured":"Andreou I, Stone PH, Ikonomidis I, et al. Recurrent atherosclerosis complications as a mechanism for stent failure. Hellenic J Cardiol 2020;61:9\u201314.","journal-title":"Hellenic J Cardiol"},{"key":"3638_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccl.2020.07.008","volume":"38","author":"A Polimeni","year":"2020","unstructured":"Polimeni A, Sorrentino S, Spaccarotella C, et al. Stent thrombosis after percutaneous coronary intervention from bare-metal to the last generation of drug-eluting stents. Cardiol Clin 2020;38:639\u2013647.","journal-title":"Cardiol Clin"},{"key":"3638_CR10","doi-asserted-by":"publisher","first-page":"151785","DOI":"10.1016\/j.aanat.2021.151785","volume":"238","author":"C Rios-Navarro","year":"2021","unstructured":"Rios-Navarro C, Daghbouche-Rubio N, Gavara J, et al. Ischemia-reperfusion injury to coronary arteries: comprehensive microscopic study after reperfused myocardial infarction. Ann Anat-Anat Anz 2021;238:151785.","journal-title":"Ann Anat-Anat Anz"},{"key":"3638_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cardfail.2009.05.001","volume":"15","author":"H Kaneko","year":"2009","unstructured":"Kaneko H, Anzai T, Naito K, et al. Role of ischemic preconditioning and inflammatory response in the development of malignant ventricular arrhythmias after reperfused ST-elevation myocardial infarction. J Card Fail 2009;15:775\u2013781.","journal-title":"J Card Fail"},{"key":"3638_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cvr\/cvz301","volume":"116","author":"LSF Konijnenberg","year":"2020","unstructured":"Konijnenberg LSF, Damman P, Duncker DJ, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc Res 2020;116:787\u2013805.","journal-title":"Cardiovasc Res"},{"key":"3638_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11883-020-00883-3","volume":"22","author":"ON Ajala","year":"2020","unstructured":"Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep 2020;22:66.","journal-title":"Curr Atheroscler Rep"},{"key":"3638_CR14","first-page":"1017","volume":"31","author":"DZ Shi","year":"2011","unstructured":"Shi DZ. Innovation and development of Academician Chen Ke-ji\u2019s methodology of disease-syndrome combination in the treatment of coronary heart disease. Chin J Integr Tradit West Med (Chin) 2011;31:1017\u20131020.","journal-title":"Chin J Integr Tradit West Med (Chin)"},{"key":"3638_CR15","first-page":"2098","volume":"42","author":"SY Liu","year":"2015","unstructured":"Liu SY, Yu DJ. Clinical experience of Weng Weiliang in the treatment of coronary heart disease after stent implantation. Liaoning J Tradit Chin Med (Chin) 2015;42:2098\u20132099.","journal-title":"Liaoning J Tradit Chin Med (Chin)"},{"key":"3638_CR16","first-page":"21","volume":"23","author":"W Meng","year":"2016","unstructured":"Meng W, Wang YH, Guo WQ. Professor GUO Wei-qin\u2019s experience on restenosis after coronary stent. Modern Chin Clin Med (Chin) 2016;23:21\u201323.","journal-title":"Modern Chin Clin Med (Chin)"},{"key":"3638_CR17","doi-asserted-by":"publisher","first-page":"120418","DOI":"10.1016\/j.biomaterials.2020.120418","volume":"269","author":"B Zhang","year":"2021","unstructured":"Zhang B, Yao R, Hu C, et al. Epigallocatechin gallate mediated sandwich-like coating for mimicking endothelium with sustained therapeutic nitric oxide generation and heparin release. Biomaterials 2021;269:120418.","journal-title":"Biomaterials"},{"key":"3638_CR18","first-page":"303","volume":"39","author":"CX Wang","year":"2018","unstructured":"Wang CX, Jia S. Advances in the mechanism of restenosis after percutaneous coronary intervention J Xi\u2019an Jiaotong Univ (Med Sci, Chin) 2018;39:303\u2013309.","journal-title":"J Xi\u2019an Jiaotong Univ (Med Sci, Chin)"},{"key":"3638_CR19","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.jacc.2010.06.045","volume":"56","author":"G Niccoli","year":"2010","unstructured":"Niccoli G, Montone RA, Ferrante G, et al. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol 2010;56:1783\u20131793.","journal-title":"J Am Coll Cardiol"},{"key":"3638_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pharmthera.2011.05.010","volume":"132","author":"MJ Butler","year":"2011","unstructured":"Butler MJ, Chan W, Taylor AJ, et al. Management of the no-reflow phenomenon. Pharmacol Ther 2011;132:72\u201385.","journal-title":"Pharmacol Ther"},{"key":"3638_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/heart.87.2.162","volume":"87","author":"T Reffelmann","year":"2002","unstructured":"Reffelmann T, Kloner RA. The \u201cno-reflow\u201d phenomenon: basic science and clinical correlates. Heart (British Cardiac Society) 2002;87:162\u2013168.","journal-title":"Heart (British Cardiac Society)"},{"key":"3638_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijcard.2015.03.359","volume":"187","author":"A Durante","year":"2015","unstructured":"Durante A, Camici PG. Novel insights into an \u201cold\u201d phenomenon: the no reflow. Int J Cardiol 2015;187:273\u2013280.","journal-title":"Int J Cardiol"},{"key":"3638_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.atherosclerosis.2018.05.022","volume":"274","author":"GP Machado","year":"2018","unstructured":"Machado GP, Araujo GNd, Carpes CK, et al. Comparison of neutrophil-to-lymphocyte ratio and mean platelet volume in the prediction of adverse events after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Atherosclerosis 2018;274:212\u2013217.","journal-title":"Atherosclerosis"},{"key":"3638_CR24","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1161\/ATVBAHA.115.306251","volume":"35","author":"ME Romero","year":"2015","unstructured":"Romero ME, Yahagi K, Kolodgie FD, et al. Neoatherosclerosis from a pathologist\u2019s point of view. Arterioscler Thromb Vasc Biol 2015;35:e43\u2013e49.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3638_CR25","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","volume":"36","author":"F Otsuka","year":"2015","unstructured":"Otsuka F, Byrne RA, Yahagi K, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J 2015;36:2147\u20132159.","journal-title":"Eur Heart J"},{"key":"3638_CR26","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jcin.2018.02.029","volume":"11","author":"M Joner","year":"2018","unstructured":"Joner M, Koppara T, Byrne RA, et al. Neoatherosclerosis in patients with coronary stent thrombosis: findings from optical coherence tomography imaging (A report of the PRESTIGE Consortium). JACC Cardiovasc Interv 2018;11:1340\u20131350.","journal-title":"JACC Cardiovasc Interv"},{"key":"3638_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","volume":"20","author":"O Soehnlein","year":"2021","unstructured":"Soehnlein O, Libby P. Targeting inflammation in atherosclerosis\u2014from experimental insights to the clinic. Nat Rev Drug Discov 2021;20:589\u2013610.","journal-title":"Nat Rev Drug Discov"},{"key":"3638_CR28","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.jacc.2011.10.909","volume":"59","author":"SJ Park","year":"2012","unstructured":"Park SJ, Kang SJ, Virmani R, et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol 2012;59:2051\u20132057.","journal-title":"J Am Coll Cardiol"},{"key":"3638_CR29","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/eurheartj\/eht090","volume":"34","author":"GM Frohlich","year":"2013","unstructured":"Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013;34:1714\u201322.","journal-title":"Eur Heart J"},{"key":"3638_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1161\/CIRCULATIONAHA.118.036044","volume":"139","author":"Q Fan","year":"2019","unstructured":"Fan Q, Tao R, Zhang H, et al. Dectin-1 contributes to myocardial ischemia\/reperfusion injury by regulating macrophage polarization and neutrophil infiltration. Circulation 2019;139:663\u2013678.","journal-title":"Circulation"},{"key":"3638_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/cvr\/cvy293","volume":"115","author":"J Tunon","year":"2019","unstructured":"Tunon J, Badimon L, Bochaton-Piallat ML, et al. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res 2019;115:10\u201319.","journal-title":"Cardiovasc Res"},{"key":"3638_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0735-1097(00)00771-3","volume":"36","author":"D Ferro","year":"2000","unstructured":"Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427\u2013431.","journal-title":"J Am Coll Cardiol"},{"key":"3638_CR33","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"PM Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959\u20131965.","journal-title":"N Engl J Med"},{"key":"3638_CR34","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1160\/TH13-03-0238","volume":"110","author":"R Suades","year":"2013","unstructured":"Suades R, Padr\u00f3 T, Alonso R, et al. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost 2013;110:366\u2013377.","journal-title":"Thromb Haemost"},{"key":"3638_CR35","doi-asserted-by":"publisher","first-page":"e0142430","DOI":"10.1371\/journal.pone.0142430","volume":"10","author":"C Tie","year":"2015","unstructured":"Tie C, Gao K, Zhang N, et al. Ezetimibe attenuates atherosclerosis associated with lipid reduction and inflammation inhibition. PLoS One 2015;10:e0142430.","journal-title":"PLoS One"},{"key":"3638_CR36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1160\/TH14-11-0947","volume":"114","author":"KA Muller","year":"2015","unstructured":"Muller KA, Chatterjee M, Rath D, et al. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost 2015;114:498\u2013518.","journal-title":"Thromb Haemost"},{"key":"3638_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1160\/TH14-12-1068","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost 2015;114:490\u2013497.","journal-title":"Thromb Haemost"},{"key":"3638_CR38","doi-asserted-by":"publisher","first-page":"e22279","DOI":"10.1002\/jbt.22279","volume":"33","author":"XL Wang","year":"2019","unstructured":"Wang XL, Deng HF, Li T, et al. Clopidogrel reduces lipopolysaccharide-induced inflammation and neutrophilplatelet aggregates in an experimental endotoxemic model. J Biochem Mol Toxicol 2019;33:e22279.","journal-title":"J Biochem Mol Toxicol"},{"key":"3638_CR39","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179\u20131189.","journal-title":"N Engl J Med"},{"key":"3638_CR40","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706\u20131717.","journal-title":"N Engl J Med"},{"key":"3638_CR41","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jcp.27205","volume":"234","author":"R Ranjbar","year":"2019","unstructured":"Ranjbar R, Shafiee M, Hesari A, et al. The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases. J Cell Physiol 2019;234:2277\u20132295.","journal-title":"J Cell Physiol"},{"key":"3638_CR42","first-page":"1167","volume":"55","author":"Expert Committee of Interventional Cardiology of China Association of Chinese Medicine","year":"2014","unstructured":"Expert Committee of Interventional Cardiology of China Association of Chinese Medicine. Consensus of TCM experts in diagnosis and treatment of chest pain after percutaneous coronary intervention (PCI). J Tradit Chin Med (Chin) 2014;55:1167\u20131170.","journal-title":"J Tradit Chin Med (Chin)"},{"key":"3638_CR43","first-page":"17","volume":"37","author":"B Cheng","year":"2017","unstructured":"Cheng B, Li XY, Liu KQ, et al. Suggestions of Chinese experts on clinical application of Compound Danshen Dropping Pills. Chin J Integr Tradit West Med (Chin) 2017;37:17\u201322.","journal-title":"Chin J Integr Tradit West Med (Chin)"},{"key":"3638_CR44","doi-asserted-by":"publisher","first-page":"5067137","DOI":"10.1155\/2020\/5067137","volume":"2020","author":"C Li","year":"2020","unstructured":"Li C, Li Q, Xu J, et al. The efficacy and safety of Compound Danshen Dripping Pill combined with percutaneous coronary intervention for coronary heart disease. Evid Based Complement Alternat Med 2020;2020:5067137.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3638_CR45","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.21037\/apm-20-1056","volume":"9","author":"A X","year":"2020","unstructured":"A X, Li Z, Luo W, et al. Long-term Compound Danshen Dripping Pills therapy reduces the no-reflow phenomenon in nondiabetes mellitus patients after primary percutaneous coronary intervention for acute myocardial infarction. Ann Palliat Med 2020;9:1144\u20131151.","journal-title":"Ann Palliat Med"},{"key":"3638_CR46","first-page":"74","volume":"17","author":"FL Shi","year":"2019","unstructured":"Shi FL. Effects of Compound Danshen Dripping Pills on serum inflammatory factors and ventricular remodeling in patients with acute myocardial infarction. Chin J Geriatric Care (Chin) 2019;17:74\u201376.","journal-title":"Chin J Geriatric Care (Chin)"},{"key":"3638_CR47","first-page":"120","volume":"24","author":"JL Pan","year":"2017","unstructured":"Pan JL, Jia GJ, Wang M. Effect of Compound Danshen Dropping Pill on the inflammatory response mediated by NF-\u03baB p65 in patients with acute myocardial infarction. Pharm Biotechnol (Chin) 2017;24:120\u2013123.","journal-title":"Pharm Biotechnol (Chin)"},{"key":"3638_CR48","first-page":"74","volume":"43","author":"ZT Cui","year":"2015","unstructured":"Cui ZT, Wei WL, Yao JM, et al. Research progress on the protective effect of Qishen Yiqi Dropping Pill on ischemic cardiomyocytes. Clin J Med Officers (Chin) 2015;43:74\u201377, 94.","journal-title":"Clin J Med Officers (Chin)"},{"key":"3638_CR49","first-page":"434","volume":"26","author":"JR Chen","year":"2015","unstructured":"Chen JR, Wei J, Zhu LJ, et al. Progress of pharmacologilal effects on cardiovascular system diseases of Qishen yiqi Dripping Pills. Lishizhen Med Mater Med Res (Chin) 2015;26:434\u2013437.","journal-title":"Lishizhen Med Mater Med Res (Chin)"},{"key":"3638_CR50","first-page":"501","volume":"29","author":"Q Yang","year":"2017","unstructured":"Yang Q, Cao YS. Study on mechanisms and myocardial protective effect of Qishen Yiqi Dropping Pills on rats with myocardial infarction. Chin Critic Care Med (Chin) 2017;29:501\u2013505.","journal-title":"Chin Critic Care Med (Chin)"},{"key":"3638_CR51","first-page":"78","volume":"25","author":"L Cheng","year":"2019","unstructured":"Cheng L, Meng GTY, Liang JG. Myocardial protection effect of Qishen Yiqi Dropping Pills on patients after PCI and control effect and mechanism on cardiac adverse events. Chin J Exp Tradit Med Form (Chin) 2019;25:78\u201384.","journal-title":"Chin J Exp Tradit Med Form (Chin)"},{"key":"3638_CR52","first-page":"38","volume":"18","author":"QQ Jing","year":"2016","unstructured":"Jing QQ, Yao L. Effects of Qishen Yiqi Droplet on the early stage of PCI postoperative inflammatory cytokines. J Hubei Univ Chin Med (Chin) 2016;18:38\u201340.","journal-title":"J Hubei Univ Chin Med (Chin)"},{"key":"3638_CR53","first-page":"1409","volume":"47","author":"Q Liu","year":"2016","unstructured":"Liu Q, Lv C, Zhang WD, et al. Advance in modern studies on Shexiang Baoxin Pill. Chin Tradit Herbal Drugs (Chin) 2016;47:1409\u20131417.","journal-title":"Chin Tradit Herbal Drugs (Chin)"},{"key":"3638_CR54","first-page":"145","volume":"38","author":"WH Fan","year":"2018","unstructured":"Fan WH, Wu ZG, Shi HM. Chinese experts\u2019 consensus on Shexiang Baoxin Pill in the treatment of coronary heart disease and angina pectoris. Chin J Integr Tradit West Med (Chin) 2018;38:145\u2013153.","journal-title":"Chin J Integr Tradit West Med (Chin)"},{"key":"3638_CR55","first-page":"912","volume":"38","author":"ZH Chen","year":"2013","unstructured":"Chen ZH, Ma L. Effects of Shexiang Baoxin Pill on inflammation indicators, cardiac and vascular endothelial function in patients with acute myocardial infarction. J Chongqing Med Univ (Chin) 2013;38:912\u2013914.","journal-title":"J Chongqing Med Univ (Chin)"},{"key":"3638_CR56","first-page":"227","volume":"14","author":"YX Huang","year":"2019","unstructured":"Huang YX, Fang KF, Zhang YH, et al. Effects of Shexiang Baoxin Pills on TCM symptoms and in-stent restenosis in the patients with acute myocardial infarction after PCI. World J Integr Tradit West Med (Chin) 2019;14:227\u2013231.","journal-title":"World J Integr Tradit West Med (Chin)"},{"key":"3638_CR57","first-page":"3698","volume":"16","author":"HL Feng","year":"2018","unstructured":"Feng HL. Effect of Shexiang Baoxin Pill on inflammatory factors and incidence of MACE in patients with angina pectoris after PCI. Chin J Integr Med Cardio-Cerebrovasc Dis (Chin) 2018;16:3698\u20133700.","journal-title":"Chin J Integr Med Cardio-Cerebrovasc Dis (Chin)"},{"key":"3638_CR58","doi-asserted-by":"crossref","unstructured":"Mao C, Fu XH, Yuan JQ, et al. Tongxinluo Capsule for patients with coronary heart disease after percutaneous coronary intervention. Cochrane Database Syst Rev 2015;CD010237.","DOI":"10.1002\/14651858.CD010237.pub2"},{"key":"3638_CR59","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fphar.2018.00830","volume":"9","author":"M Li","year":"2018","unstructured":"Li M, Li C, Chen S, et al. Potential effectiveness of Chinese patent medicine for secondary prevention after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2018;9:830.","journal-title":"Front Pharmacol"},{"key":"3638_CR60","first-page":"1805","volume":"26","author":"YT Huang","year":"2017","unstructured":"Huang YT. Effects of Tongxinluo Capsule combined with tirofiban on in-stent thrombosis and inflammatory factors in patients with acute myocardial infarction after PCI. Modern J Integr Tradit Chin West Med (Chin) 2017;26:1805\u20131807.","journal-title":"Modern J Integr Tradit Chin West Med (Chin)"},{"key":"3638_CR61","first-page":"6087","volume":"46","author":"HQ Geng","year":"2021","unstructured":"Geng HQ, Xie YM, Wang ZF. Clinical comprehensive evaluation of Naoxintong Capsules in treatment of cerebral infarction with qi deficiency and blood stasis syndrome and coronary heart disease angina pectoris. China J Chin Mater Med (Chin) 2021;46:6087\u20136095.","journal-title":"China J Chin Mater Med (Chin)"},{"key":"3638_CR62","first-page":"1442","volume":"8","author":"KH Ma","year":"2013","unstructured":"Ma KH. Buchang Naoxintong Capsule on blood lipid level in acute coronary syndrome and hypersensitive C-reactive protein. World Chin Med (Chin) 2013;8:1442\u20131444.","journal-title":"World Chin Med (Chin)"},{"key":"3638_CR63","first-page":"225","volume":"20","author":"WW Feng","year":"2014","unstructured":"Feng WW, Xiong B, Sun LJ. Effect of Naoxintong Capsule on endothelial function in patients with coronary heart disease after PCI operation. Chin J Exp Tradit Med Form (Chin) 2014;20:225\u2013228.","journal-title":"Chin J Exp Tradit Med Form"},{"key":"3638_CR64","first-page":"3800","volume":"27","author":"A Wang","year":"2016","unstructured":"Wang A, Wang CD. Effect of Naoxintong Capsule on the myocardial perfusion and platelet activation function in patients with acute myocardial infarction after PCI. China Pharm (Chin) 2016;27:3800\u20133802.","journal-title":"China Pharm (Chin)"},{"key":"3638_CR65","first-page":"188","volume":"27","author":"YY Chen","year":"2021","unstructured":"Chen YY, Li H, Wu P, et al. Research progress on pharmacological mechanism of Danhong Injection in treatment of cardiovascular and cerebrovascular diseases. Chin J Exp Tradit Med Formul (Chin) 2021;27:188\u2013196.","journal-title":"Chin J Exp Tradit Med Formul (Chin)"},{"key":"3638_CR66","first-page":"389","volume":"38","author":"CG Fu","year":"2018","unstructured":"Fu CG, Liu LT, Wang YF, et al. Chinese experts consensus on application of Danhong Injection. Chin J Integr Tradit West Med (Chin) 2018;38:389\u2013397.","journal-title":"Chin J Integr Tradit West Med (Chin)"},{"key":"3638_CR67","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jep.2015.08.026","volume":"174","author":"X Jiang","year":"2015","unstructured":"Jiang X, Lv B, Li P, et al. Bioactivity-integrated UPLC\/Q-TOF-MS of Danhong Injection to identify NF-\u03baB inhibitors and anti-inflammatory targets based on endothelial cell culture and network pharmacology. J Ethnopharmacol 2015;174:270\u2013276.","journal-title":"J Ethnopharmacol"},{"key":"3638_CR68","first-page":"2134","volume":"20","author":"XY Yang","year":"2018","unstructured":"Yang XY, Xing YW, Shang HC. Danhong Injection on inflammatory factors after percutaneous coronary intervention in patients with coronary heart disease: a meta-analysis. Modern Tradit Chin Med Mater Med-World Sci Technol (Chin) 2018;20:2134\u20132140.","journal-title":"Modern Tradit Chin Med Mater Med-World Sci Technol (Chin)"},{"key":"3638_CR69","first-page":"154","volume":"21","author":"JF Guo","year":"2015","unstructured":"Guo JF, Wu SB, Yang JP, et al.Treatment of Danhong Injection with atorvastatin on endothelial function and inflammation factors in patients with acute coronary syndrome after percutaneous coronary intervention. Chin J Exp Tradit Med Form (Chin) 2015;21:154\u2013157.","journal-title":"Chin J Exp Tradit Med Form (Chin)"},{"key":"3638_CR70","first-page":"186","volume":"24","author":"T Zhang","year":"2018","unstructured":"Zhang T, Chen H, Huang JS, et al. Effect of Danhong Injection on adverse cardiac events after percutaneous coronary intervention. Chin J Exp Tradit Med Form (Chin) 2018;24:186\u2013191.","journal-title":"Chin J Exp Tradit Med Form (Chin)"}],"container-title":["Chinese Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-023-3638-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11655-023-3638-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-023-3638-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T09:20:47Z","timestamp":1688203247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11655-023-3638-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3638"],"URL":"https:\/\/doi.org\/10.1007\/s11655-023-3638-8","relation":{},"ISSN":["1672-0415","1993-0402"],"issn-type":[{"value":"1672-0415","type":"print"},{"value":"1993-0402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"3 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}